Form 4: Oruka Therapeutics Director Sells Shares
Insider Transaction (Form 4)
Kristine M Ball, a Director of Oruka Therapeutics, Inc., sold 18,000 shares of common stock on November 12, 2026.
Summary
- Option exercise/conversion: acquired 18,000 Common Stock at $6.84 ($123,120) on November 12, 2026; holds 18,000 after (Direct).
- Open-market sale: disposed of 1,196 Common Stock at $102.10 ($122,108) on November 12, 2026; holds 16,804 after (Direct).
- Open-market sale: disposed of 1,300 Common Stock at $103.09 ($134,021) on November 12, 2026; holds 15,504 after (Direct).
- Open-market sale: disposed of 2,039 Common Stock at $104.16 ($212,387) on November 12, 2026; holds 13,465 after (Direct).
- Open-market sale: disposed of 10,765 Common Stock at $105.31 ($1,133,706) on November 12, 2026; holds 2,700 after (Direct).
- Open-market sale: disposed of 2,500 Common Stock at $106.05 ($265,130) on November 12, 2026; holds 200 after (Direct).
- Open-market sale: disposed of 200 Common Stock at $106.98 ($21,397) on November 12, 2026 (Direct).
- Option exercise/conversion: disposed of 18,000 Stock Option (Right to Buy) on November 12, 2026; holds 53,426 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $1,888,749 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Kristine M Ball — Director
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-11-12 | Option exercise/conversion | Common Stock | 18,000 | $7 | $123.1K | 18,000 |
| 2026-11-12 | Open-market sale | Common Stock | 1,196 | $102 | $122.1K | 16,804 |
| 2026-11-12 | Open-market sale | Common Stock | 1,300 | $103 | $134.0K | 15,504 |
| 2026-11-12 | Open-market sale | Common Stock | 2,039 | $104 | $212.4K | 13,465 |
| 2026-11-12 | Open-market sale | Common Stock | 10,765 | $105 | $1.1M | 2,700 |
| 2026-11-12 | Open-market sale | Common Stock | 2,500 | $106 | $265.1K | 200 |
| 2026-11-12 | Open-market sale | Common Stock | 200 | $107 | $21.4K | 0 |
| 2026-11-12 | Option exercise/conversion | Stock Option (Right to Buy) | 18,000 | — | — | 53,426 |
Key Dates
| Date | Description |
|---|---|
| 2026-11-12 | Option exercise/conversion (18,000 shares) |
| 2026-11-12 | Open-market sale (1,196 shares) |
| 2026-11-12 | Open-market sale (1,300 shares) |
| 2026-11-12 | Open-market sale (2,039 shares) |
| 2026-11-12 | Open-market sale (10,765 shares) |
| 2026-11-12 | Open-market sale (2,500 shares) |
| 2026-11-12 | Open-market sale (200 shares) |
| 2026-11-12 | Option exercise/conversion (18,000 shares) |
Keywords
insider transaction, Form 4, ORKA, Oruka Therapeutics, Inc., bearish, Kristine M Ball
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.